Efficacy and Safety of BG00012 in MS
NCT00168701 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 260
Last updated 2023-08-28
Summary
Determine the efficacy, safety, and tolerability of BG00012 in MS patients.
Conditions
Interventions
- DRUG
-
BG00012
Sponsors & Collaborators
- lead INDUSTRY
Principal Investigators
-
Ludwig Kappos, Prof · Kantonsspital Basel
-
Gilmore O'Neill, MB,MRCPI,MMedSc · Biogen
Study Design
- Allocation
- RANDOMIZED
- Purpose
- TREATMENT
- Masking
- DOUBLE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Max Age
- 55 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2004-10-01
- Primary Completion
- 2006-03-31
- Completion
- 2006-03-31
Countries
- Czechia
- Germany
- Hungary
- Netherlands
- Poland
- Russia
- Sweden
- Switzerland
- Turkey (Türkiye)
- United Kingdom
Study Locations
More Related Trials
-
Exploratory Study of the Safety, Tolerability and Efficacy of Multiple Regimens of Natalizumab in Adult Participants With Relapsing Multiple Sclerosis (MS)
NCT01405820 ·Status: COMPLETED ·Phase: PHASE2
-
BG00012 and Delay of Disability Progression in Secondary Progressive Multiple Sclerosis
NCT02430532 ·Status: TERMINATED ·Phase: PHASE3
-
Effect of BG00012 on Lymphocyte Subsets and Immunoglobulins in Subjects With Relapsing Remitting Multiple Sclerosis (RRMS).
NCT02525874 ·Status: COMPLETED ·Phase: PHASE3
-
An Efficacy and Safety Study of BG00012 (Dimethyl Fumarate) in Asian Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01838668 ·Status: COMPLETED ·Phase: PHASE3
-
Study to Explore the Onset of Efficacy on Magnetic Resonance Disease Activity of BG00012 (Dimethyl Fumarate) in Patients With Relapsing remitTing Multiple Sclerosis
NCT02472938 ·Status: WITHDRAWN ·Phase: PHASE4
-
Safety and Efficacy of Natalizumab in the Treatment of Multiple Sclerosis
NCT00027300 ·Status: COMPLETED ·Phase: PHASE3
-
Extension Study of BG00012 in Pediatric Subjects With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT02555215 ·Status: COMPLETED ·Phase: PHASE3
-
Placebo-Controlled Study of the Efficacy and Safety of BG00012 in Pediatric Subjects With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT02428218 ·Status: WITHDRAWN ·Phase: PHASE3
-
COVID-19 Vaccine Response in Treated MS Patients
NCT05060354 ·Status: COMPLETED
-
Natalizumab (BG00002, Tysabri) Study in Japanese Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT01440101 ·Status: COMPLETED ·Phase: PHASE2/PHASE3
-
Safety and Efficacy of Fingolimod in MS Patients in China
NCT01941004 ·Status: WITHDRAWN ·Phase: PHASE3
-
Extension Study to Evaluate Safety and Efficacy of Natalizumab in Japanese Participants With Relapsing-Remitting Multiple Sclerosis
NCT01416155 ·Status: COMPLETED ·Phase: PHASE2
-
A Study to Assess the Effects of MK0812 on Disease Activity in Patients With Relapsing-Remitting Multiple Sclerosis as Measured by Magnetic Resonance Imaging (MRI)(0812-003)(COMPLETED)
NCT00239655 ·Status: TERMINATED ·Phase: PHASE2
-
Biologic Basis for Multiple Sclerosis Disease Progression in RRMS Patients Treated With Gilenya
NCT02137707 ·Status: COMPLETED
-
A Study to Investigate Multiple Sclerosis Relapse Prevention With mRNA-1195 Compared With Placebo in Participants Aged 18 to ≤55 Years
NCT06735248 ·Status: RECRUITING ·Phase: PHASE2
-
Efficacy and Safety of MBP8298 in Subjects With Secondary Progressive Multiple Sclerosis
NCT00468611 ·Status: TERMINATED ·Phase: PHASE3
-
A 24-Hour Pharmacokinetic Determination of BG00012 After Single-Day Oral Administration in Subjects With MS
NCT00837785 ·Status: COMPLETED ·Phase: PHASE1
-
A Study to Assess the Safety and Efficacy of Elezanumab When Added to Standard of Care in Progressive Forms of Multiple Sclerosis
NCT03737812 ·Status: COMPLETED ·Phase: PHASE2
-
Efficacy and Safety of Remibrutinib Compared to Teriflunomide in Participants With Relapsing Multiple Sclerosis (RMS)
NCT05147220 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE3
-
Natalizumab Subcutaneous Immunogenicity and Safety Study
NCT02142192 ·Status: TERMINATED ·Phase: PHASE2
-
The Efficacy, Safety, and Tolerability of Laquinimod in Participants With Relapsing Remitting Multiple Sclerosis (RRMS)
NCT01707992 ·Status: COMPLETED ·Phase: PHASE3
-
Phase 3 Efficacy and Safety Study of BG00012 in Pediatric Participants With Relapsing-Remitting Multiple Sclerosis (RRMS)
NCT02283853 ·Status: COMPLETED ·Phase: PHASE3
-
Three Months Treatment With SB683699 In Patients With Relapsing Multiple Sclerosis
NCT00097331 ·Status: COMPLETED ·Phase: PHASE2
-
Study Assessing Cognition in Relapsing Remitting Multiple Sclerosis (RRMS) Patients Treated With BG00012
NCT02579681 ·Status: COMPLETED ·Phase: PHASE3
-
Safety, Tolerability, Efficacy and Optimal Dose Finding Study of BAF312 in Patients With Relapsing-remitting Multiple Sclerosis
NCT00879658 ·Status: COMPLETED ·Phase: PHASE2